{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:26:25Z","timestamp":1792113985443,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.xphs.2023.10.019","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:26:42Z","timestamp":1697311602000},"page":"72-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrated PK\/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models"],"prefix":"10.1016","volume":"113","author":[{"given":"Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Ruszaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-0440","authenticated-orcid":false,"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-9236","authenticated-orcid":false,"given":"Robert M.","family":"Straubinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2023.10.019_bib0001","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.019_bib0002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2217\/1750743X.1.2.223","article-title":"Monoclonal antibodies in the treatment of pancreatic cancer","volume":"1","author":"Huang","year":"2009","journal-title":"Immunotherapy"},{"issue":"5933","key":"10.1016\/j.xphs.2023.10.019_bib0003","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.019_bib0004","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.019_bib0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"issue":"19","key":"10.1016\/j.xphs.2023.10.019_bib0006","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tredan","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.019_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004142","article-title":"Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy","volume":"11","author":"Fu","year":"2015","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.019_bib0008","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1208\/s12248-012-9357-2","article-title":"Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts","volume":"14","author":"Abuqayyas","year":"2012","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.019_bib0009","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J Controll Release"},{"issue":"11","key":"10.1016\/j.xphs.2023.10.019_bib0010","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/1535-7163.MCT-18-0354","article-title":"Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model","volume":"18","author":"Wang","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.019_bib0011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1535-7163.MCT-15-0602","article-title":"Tumor-priming Smoothened inhibitor enhances deposition and efficacy of cytotoxic nanoparticles in a pancreatic cancer model","volume":"15","author":"Roy Chaudhuri","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.019_bib0012","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nnano.2012.45","article-title":"Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner","volume":"7","author":"Chauhan","year":"2012","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.019_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.03.008","article-title":"Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer","volume":"181","author":"Ruscetti","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.019_bib0014","first-page":"25","article-title":"Regulation mechanisms of the hedgehog pathway in pancreatic cancer: a review","volume":"16","author":"Honselmann","year":"2015","journal-title":"JOP"},{"issue":"5897","key":"10.1016\/j.xphs.2023.10.019_bib0015","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.xphs.2023.10.019_bib0016","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1073\/pnas.0813203106","article-title":"Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis","volume":"106","author":"Tian","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.xphs.2023.10.019_bib0017","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-08-0291","article-title":"Sonic hedgehog promotes desmoplasia in pancreatic cancer","volume":"14","author":"Bailey","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.xphs.2023.10.019_bib0018","doi-asserted-by":"crossref","first-page":"E3091","DOI":"10.1073\/pnas.1411679111","article-title":"Stromal response to Hedgehog signaling restrains pancreatic cancer progression","volume":"111","author":"Lee","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.019_bib0019","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.019_bib0020","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.xphs.2023.10.019_bib0021","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1158\/1078-0432.CCR-12-3654","article-title":"Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors","volume":"19","author":"Jimeno","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.xphs.2023.10.019_bib0022","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-14-1269","article-title":"Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma","volume":"20","author":"Kim","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.019_bib0023","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MPA.0000000000000458","article-title":"A Phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma","volume":"45","author":"Ko","year":"2016","journal-title":"Pancreas"},{"issue":"51","key":"10.1016\/j.xphs.2023.10.019_bib0024","doi-asserted-by":"crossref","first-page":"51ra70","DOI":"10.1126\/scitranslmed.3001599","article-title":"Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma","volume":"2","author":"Buonamici","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xphs.2023.10.019_bib0025","series-title":"Stromal Modulation as a Strategy to Enhance Monoclonal Antibody Deposition In Pancreatic Ductal Adenocarcinoma","first-page":"256","author":"Wang","year":"2016"},{"key":"10.1016\/j.xphs.2023.10.019_bib0026","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejpb.2021.08.019","article-title":"Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics\/pharmacodynamics model","volume":"168","author":"Wang","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.019_bib0027","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10928-013-9332-2","article-title":"Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies","volume":"40","author":"Cao","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.019_bib0028","first-page":"1517","article-title":"Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice","volume":"54","author":"Baxter","year":"1994","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.019_bib0029","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1152\/physrev.1994.74.1.163","article-title":"Transport of macromolecules across microvascular walls: the two-pore theory","volume":"74","author":"Rippe","year":"1994","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.019_bib0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J Pharmacok Pharmacodyn"},{"key":"10.1016\/j.xphs.2023.10.019_bib0031","series-title":"ADAPT 5 User's Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D'Argenio","year":"2009"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.019_bib0032","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ydbio.2012.12.018","article-title":"Sonic hedgehog signaling directly targets Hyaluronic Acid Synthase 2, an essential regulator of phalangeal joint patterning","volume":"375","author":"Liu","year":"2013","journal-title":"Dev Biol"},{"key":"10.1016\/j.xphs.2023.10.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/817613","article-title":"Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment","volume":"2014","author":"Kultti","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.019_bib0034","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10928-009-9120-1","article-title":"Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis","volume":"36","author":"Krippendorff","year":"2009","journal-title":"J Pharmacok and Pharmacodyn"},{"issue":"4","key":"10.1016\/j.xphs.2023.10.019_bib0035","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2011.09.003","article-title":"A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies","volume":"20","author":"Schaefer","year":"2011","journal-title":"Cancer Cell"},{"issue":"5A","key":"10.1016\/j.xphs.2023.10.019_bib0036","first-page":"3355","article-title":"Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface","volume":"27","author":"Patel","year":"2007","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.019_bib0037","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1039\/C4AY02174F","article-title":"A label-free approach to kinetic analysis and high multiplex detection of targeted drugs with phase surface plasmon resonance imaging","volume":"7","author":"Wang","year":"2015","journal-title":"Anal Methods"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.019_bib0060","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1152\/physrev.00037.2011","article-title":"Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer","volume":"92","author":"Wiig","year":"2012","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.019_bib0061","first-page":"19","article-title":"Catalytic enzyme activity concentration in thoracic duct, liver, and intestinal lymph of the dog, the rabbit, the rat and the mouse. Approach to a quantitative diagnostic enzymology, II. Communication","volume":"24","author":"Lindena","year":"1986","journal-title":"J Clinic Chem Clinic Biochem"},{"key":"10.1016\/j.xphs.2023.10.019_bib0054","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2019.00849","article-title":"Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors","volume":"9","author":"Garcia-Foncillas","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.019_bib0062","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"10.1016\/j.xphs.2023.10.019_bib0038","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"24 Pt 1","key":"10.1016\/j.xphs.2023.10.019_bib0039","first-page":"7022","article-title":"Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure","volume":"48","author":"Jain","year":"1988","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.xphs.2023.10.019_bib0040","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/1078-0432.CCR-07-4465","article-title":"Direct visualization of heterogeneous extravascular distribution of trastuzumab in human Epidermal Growth Factor Receptor Type 2 overexpressing xenografts","volume":"14","author":"Baker","year":"2008","journal-title":"Clinic Cancer Res"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.019_bib0041","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccell.2015.11.002","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"28","author":"Ozdemir","year":"2015","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.xphs.2023.10.019_bib0042","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.18632\/oncotarget.6770","article-title":"The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xphs.2023.10.019_bib63","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-0975","article-title":"Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation","volume":"17","author":"Wong","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.019_bib0043","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nsmb.1833","article-title":"DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS","volume":"17","author":"Lauth","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"4-5","key":"10.1016\/j.xphs.2023.10.019_bib0044","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1387\/ijdb.103213sp","article-title":"Signal transduction in vasculogenesis and developmental angiogenesis","volume":"55","author":"Patel-Hett","year":"2011","journal-title":"Int J Dev Biol"},{"issue":"10","key":"10.1016\/j.xphs.2023.10.019_bib0045","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1021\/ac2034166","article-title":"High-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography\/selected reaction monitoring mass spectrometry","volume":"84","author":"Duan","year":"2012","journal-title":"Anal Chem"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.019_bib0046","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/jps.21918","article-title":"Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody","volume":"99","author":"Urva","year":"2010","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2023.10.019_bib0047","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1124\/dmd.114.060319","article-title":"Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution","volume":"42","author":"Conner","year":"2014","journal-title":"Drug Metabol Disposit"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.019_bib0048","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1113\/jphysiol.2005.089615","article-title":"The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components","volume":"567","author":"Wiig","year":"2005","journal-title":"J Physiol"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.019_bib0049","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/jpet.108.149443","article-title":"Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy","volume":"329","author":"Shah","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.019_bib0050","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","article-title":"Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy","volume":"18","author":"Cilliers","year":"2016","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.019_bib0051","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1208\/s12248-019-0391-1","article-title":"An agent-based systems pharmacology model of the antibody-drug conjugate kadcyla to predict efficacy of different dosing regimens","volume":"22","author":"Menezes","year":"2020","journal-title":"AAPS J"},{"issue":"5A","key":"10.1016\/j.xphs.2023.10.019_bib0052","first-page":"3355","article-title":"Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface","volume":"27","author":"Patel","year":"2007","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.xphs.2023.10.019_bib0053","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.placenta.2011.04.008","article-title":"Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models","volume":"32","author":"Ledon","year":"2011","journal-title":"Placenta"},{"key":"10.1016\/j.xphs.2023.10.019_bib0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.isci.2019.05.003","article-title":"A bioluminescence resonance energy transfer-based approach for determining antibody-receptor occupancy in vivo","volume":"15","author":"Tang","year":"2019","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.019_bib0056","doi-asserted-by":"crossref","first-page":"16764","DOI":"10.1038\/s41598-020-73711-y","article-title":"Modeling the dynamics of antibody-target binding in living tumors","volume":"10","author":"Tang","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.xphs.2023.10.019_bib0057","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41416-020-01046-6","article-title":"Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer","volume":"123","author":"Greene","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.xphs.2023.10.019_bib0058","article-title":"Reshaping the tumor stroma for treatment of pancreatic cancer","author":"Vennin","year":"2017","journal-title":"Gastroenterology"},{"issue":"49","key":"10.1016\/j.xphs.2023.10.019_bib0059","doi-asserted-by":"crossref","first-page":"84635","DOI":"10.18632\/oncotarget.21468","article-title":"Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy","volume":"8","author":"Vennin","year":"2017","journal-title":"Oncotarget"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923004276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923004276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:44:04Z","timestamp":1758361444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923004276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0022354923004276"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.10.019","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated PK\/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}